相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 保存条件:
常温,避光
- 克隆性:
单克隆
- 抗体名:
Coagulation Factor XI / F11抗体
免疫原 :
Recombinant Human Coagulation Factor XI / F11 protein (Catalog#10302-H08H)
Antibody Type : Rabbit Monoclonal Antibody ( Rabbit mAb Service Platform )
克隆号 :
007
抗体宿主 :
Rabbit IgG
缓冲液 : 0.2 μm filtered solution in PBS, 5% trehalose may be added in some batches. Please read the hardcopy of COA or contact our customer service to confirm the formulation.
制备方法 :
This antibody was obtained from a rabbit immunized with purified, recombinant Human Coagulation Factor XI / F11 (rh Coagulation Factor XI / F11; Catalog#10302-H08H; NP_000119.1; Met1-Val625).
Coagulation Factor XI / F11抗体 Background
Factor XI (plasma thromboplastin antecedent) is a plasma glycoprotein, and a zymogen acting as a serine protease which participates in blood coagulation as a catalyst in the conversion of factor IX to factor IXa in the presence of calcium ions. The factor XI is synthesized in the liver as a single polypeptide chain with a molecular weight estimated between 125 ~160 kDa and then is processed into a disulfide-bond linked homodimer. Factor XI is is converted to an active protease, factor XIa, by factor XIIa (or factor XII) in the presence of high molecular weight kininogen (HMWK) and a polyanionic surface. After the activation reaction, Factor XIa is composed of two heavy and two light chains held together by three disulfide bonds. The heavy chains are derived from the amino termini of the zymogen and responsible for the binding of factor XI to high molecular weight kininogen and for the activation of factor IX, while the light chain contains the catalytic portion of the enzyme and is homologous to the trypsin family of serine proteases. FXI deficiency is a disorder characterized by a mild or no bleeding tendency. The vast majority of the FXI deficiencies have been found in the Ashkenazi Jewish population.
Coagulation Factor XI / F11抗体相关产品如下:
hz-1689R MEK3丝裂原活化蛋白激酶MKK3抗体
hz-2166R MYSM1MYSM1抗体
hz-1569R MCT1单羧酸转运蛋白-1抗体
hz-1847R MAP1A微管相关蛋白1A抗体
hz-1849R Midkine中期因子/肝素结合生长因子抗体
hz-1850R Mineralocorticoid receptor盐皮质激素受体抗体
hz-1848R alpha MSH促黑细胞激素α抗体
hz-4122R MAX proteinMyc基因相关X因子抗体
hz-1425R ASK1细胞凋亡信号调节激酶1抗体
hz-5424R MAP3K7IP3NFKB激活蛋白1抗体
hz-5425R phospho-MAX protein(Tyr123)磷酸化Myc基因相关X因子抗体
hz-1484R MTHFR亚甲基四氢叶酸还原酶MTHFR抗体
hz-1433R MEK1MEK1/MAPKK1抗体(N-端)
hz-0963R MTNR1B褪黑素受体1B抗体
hz-1422R MRP4多药耐药相关蛋白4抗体
hz-1437R MRP5多药耐药相关蛋白5抗体
hz-1824R Mitofilin线粒体内膜蛋白抗体
hz-1913R MMP-8基质金属蛋白酶-8/胶原酶2抗体
hz-1853R MMP-11基质金属蛋白酶11抗体
hz-1854R MMP-12基质金属蛋白酶-12抗体
hz-1855R MMP-15基质金属蛋白酶-15抗体
hz-1856R MMP-16基质金属蛋白酶-16抗体
hz-1862R MMP-17基质金属蛋白酶-17抗体
hz-1802R Moesin膜突蛋白抗体
hz-0886R Measles virus fusion protein麻疹病毒融合蛋白抗体
hz-9522R MPP1红细胞膜蛋白55抗体
hz-9339R MARCH5膜相关环指蛋白5抗体
hz-5481R phospho-MEF2C(Ser387)磷酸化肌细胞增强因子2C抗体
hz-13764R MRP63线粒体核糖体蛋白MRP63抗体
hz-5482R phospho-MEF2C(Thr20)磷酸化肌细胞增强因子2C抗体
hz-10250R MMP13基质金属蛋白酶13抗体
hz-11525R MICAL1酪氨酸单氧化酶微管相关蛋白MICAL抗体
hz-11513R MKS1梅克尔-格鲁伯综合征相关蛋白抗体
hz-6811R MUM1突变的黑色素瘤相关抗原1抗体
hz-6816R MAGEA10黑色素瘤相关抗原10抗体
hz-6301R MAP3K2丝裂原活化蛋白激酶激酶2抗体
hz-6626R GPR24G蛋白偶联受体24抗体
hz-6722R MAPK organizer 1丝裂原活化蛋白激酶组织蛋白1抗体
hz-6680R MEIS1同源盒蛋白Meis1抗体
hz-6679R MAOA单氨氧化酶A抗体
hz-8512R MSX1MSH同源蛋白1样蛋白抗体
hz-9340R MARCH6膜相关环指蛋白6抗体
hz-5787R MMP19基质金属蛋白酶18/19
风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验Molecular Analysis in Factor XI Deficiency
Factor XI (FXI) is the zymogen precursor of an active serine protease that participates in the contact phase of coagulation. Synthesized in the liver, it circulates in the plasma in a noncovalent complex with high molecular weight kininogen
Studies on Coagulation Incompatibilities for Xenotransplantation
) circulating PC in the presence of thrombin. Tissue factor pathway inhibitor (TFPI), is the primary inhibitor of tissue factor (TF)-induced coagulation. TFPI directly inhibits the activated factor X (FXa) and blocks the procoagulant activity of the TF/factor
Identification of Mutations in the Human Factor VII Gene
It has been recognized from the early 1800s that activation of coagulation can be initiated by the exposure of subendothelial layers (tissue factor), but it was the 1940s before factor VII (FVII) was included in this event
技术资料暂无技术资料 索取技术资料




